[Clinical studies of cefotiam in the field of otorhinolaryngology].
Cefotiam (CTM) was intravenously given to 20 patients with infections in the field of otorhinolaryngology. Daily doses of CTM were 2 to 4 g divided into 2. Clinical responses were excellent in 11 patients, good in 8 and fair in 1, the rate of satisfactory clinical responses being 95% (19/20). Ninety-one % (10/11) of Gram-positive cocci isolated from the patients were eradicated by the CTM treatment, while 60% (6/10) of Gram-negative bacilli were persisted. As for the side effects, eruption and elevation of GOT and GPT were observed in 1 patient.
D000293:Adolescent; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015310:Cefotiam; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000382:microbiology
D015310:Cefotiam; D002439:Cefotaxime